On Nov 01, major Wall Street analysts update their ratings for $Eli Lilly and Co (LLY.US)$, with price targets ranging from $970 to $1,146.
Morgan Stanley analyst Terence Flynn maintains with a buy rating, and adjusts the target price from $1,158 to $1,146.
BofA Securities analyst Alec Stranahan maintains with a buy rating, and adjusts the target price from $1,150 to $1,100.
Barclays analyst Carter Gould maintains with a buy rating, and adjusts the target price from $1,025 to $975.
Jefferies analyst Akash Tewari maintains with a buy rating, and adjusts the target price from $1,113 to $994.
Truist Financial analyst Srikripa Devarakonda maintains with a buy rating, and adjusts the target price from $1,033 to $1,029.
Furthermore, according to the comprehensive report, the opinions of $Eli Lilly and Co (LLY.US)$'s main analysts recently are as follows:
Eli Lilly's recent quarter revealed uneven results for Mounjaro and Zepbound, which were clarified as being connected to inventory dynamics rather than supply or demand factors. Despite a slight reduction in expectations for Mounjaro and Zepbound, the overall outlook on Eli Lilly remains optimistic, even considering the third-quarter irregularities.
Post the Q3 report, Eli Lilly's forecast suggests there is 'substantial work' ahead for Q4, given the tirzepatide miss, fluctuating channel inventories, and the delay of direct-to-consumer activities until mid-quarter.
Here are the latest investment ratings and price targets for $Eli Lilly and Co (LLY.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
